Cargando…

Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer

BACKGROUND: Chemoresistance is a major contributing factor to cancer treatment failure. Emerging research reveals that circular RNA (circRNA) dysregulation is implicated in chemoresistance. Our current study aimed to investigate the involvement of hsa_circ_0092887 in paclitaxel (PTX) resistance in n...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Limei, Zhang, Zhiyong, Tian, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833980/
https://www.ncbi.nlm.nih.gov/pubmed/36550019
http://dx.doi.org/10.1002/jcla.24781
_version_ 1784868359948468224
author Wang, Limei
Zhang, Zhiyong
Tian, Hui
author_facet Wang, Limei
Zhang, Zhiyong
Tian, Hui
author_sort Wang, Limei
collection PubMed
description BACKGROUND: Chemoresistance is a major contributing factor to cancer treatment failure. Emerging research reveals that circular RNA (circRNA) dysregulation is implicated in chemoresistance. Our current study aimed to investigate the involvement of hsa_circ_0092887 in paclitaxel (PTX) resistance in non‐small cell lung cancer (NSCLC). METHODS: RT‐qPCR as well as western blotting were used for the analysis of hsa_circ_0092887, miR‐490‐5p and UBE2T expression in PTX‐resistant NSCLC tumor tissues and cells. CCK‐8 assay was done to determine the IC50 value of PTX. CCK‐8 assay, wound healing assay, analysis of apoptosis related proteins (Bax and Bcl‐2), and xenograft mouse models were utilized to investigate the role of hsa_circ_0092887 in PTX‐resistance in NSCLC. The binding sites of miR‐490‐5p to hsa_circ_0092887 or UBE2T were predicted by bioinformatics tools and were verified by RIP and dual‐luciferase assays. RESULTS: Expression of hsa_Circ_0092887 was upregulated in NSCLC tumor samples/cell lines, and its expression was also higher in PTX‐resistant tumor samples/cell lines when compared with their respective controls. Silencing of hsa_circ_0092887 in PTX‐treated NSCLC cells inhibited cell proliferation and migration, induced apoptosis, and suppressed tumor growth in xenograft mouse models in vivo. MiR‐490‐5p was a direct target of hsa_circ_0092887, and UBE2T was a functional downstream target of hsa_circ_0092887/miR‐490‐5p axis. Hsa_circ_0092887 depletion‐induced anti‐cancer effects in PTX‐treated NSCLC cells were reversed by miR‐490‐5p inhibitor. Furthermore, inhibition of miR‐490‐5p strengthened UBE2T expression, thereby attenuating the anti‐cancer effects caused by UBE2T knockdown. CONCLUSION: Hsa_circ_0092887 depletion alleviated PTX‐resistance in NSCLC cells via modulating the miR‐490‐5p/UBE2T axis, and the targeted management of hsa_circ_0092887‐mediated signaling axis might contribute to PTX‐resistance intervention in NSCLC.
format Online
Article
Text
id pubmed-9833980
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98339802023-01-13 Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer Wang, Limei Zhang, Zhiyong Tian, Hui J Clin Lab Anal Research Articles BACKGROUND: Chemoresistance is a major contributing factor to cancer treatment failure. Emerging research reveals that circular RNA (circRNA) dysregulation is implicated in chemoresistance. Our current study aimed to investigate the involvement of hsa_circ_0092887 in paclitaxel (PTX) resistance in non‐small cell lung cancer (NSCLC). METHODS: RT‐qPCR as well as western blotting were used for the analysis of hsa_circ_0092887, miR‐490‐5p and UBE2T expression in PTX‐resistant NSCLC tumor tissues and cells. CCK‐8 assay was done to determine the IC50 value of PTX. CCK‐8 assay, wound healing assay, analysis of apoptosis related proteins (Bax and Bcl‐2), and xenograft mouse models were utilized to investigate the role of hsa_circ_0092887 in PTX‐resistance in NSCLC. The binding sites of miR‐490‐5p to hsa_circ_0092887 or UBE2T were predicted by bioinformatics tools and were verified by RIP and dual‐luciferase assays. RESULTS: Expression of hsa_Circ_0092887 was upregulated in NSCLC tumor samples/cell lines, and its expression was also higher in PTX‐resistant tumor samples/cell lines when compared with their respective controls. Silencing of hsa_circ_0092887 in PTX‐treated NSCLC cells inhibited cell proliferation and migration, induced apoptosis, and suppressed tumor growth in xenograft mouse models in vivo. MiR‐490‐5p was a direct target of hsa_circ_0092887, and UBE2T was a functional downstream target of hsa_circ_0092887/miR‐490‐5p axis. Hsa_circ_0092887 depletion‐induced anti‐cancer effects in PTX‐treated NSCLC cells were reversed by miR‐490‐5p inhibitor. Furthermore, inhibition of miR‐490‐5p strengthened UBE2T expression, thereby attenuating the anti‐cancer effects caused by UBE2T knockdown. CONCLUSION: Hsa_circ_0092887 depletion alleviated PTX‐resistance in NSCLC cells via modulating the miR‐490‐5p/UBE2T axis, and the targeted management of hsa_circ_0092887‐mediated signaling axis might contribute to PTX‐resistance intervention in NSCLC. John Wiley and Sons Inc. 2022-12-22 /pmc/articles/PMC9833980/ /pubmed/36550019 http://dx.doi.org/10.1002/jcla.24781 Text en © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Wang, Limei
Zhang, Zhiyong
Tian, Hui
Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer
title Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer
title_full Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer
title_fullStr Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer
title_full_unstemmed Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer
title_short Hsa_circ_0092887 targeting miR‐490‐5p/UBE2T promotes paclitaxel resistance in non‐small cell lung cancer
title_sort hsa_circ_0092887 targeting mir‐490‐5p/ube2t promotes paclitaxel resistance in non‐small cell lung cancer
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833980/
https://www.ncbi.nlm.nih.gov/pubmed/36550019
http://dx.doi.org/10.1002/jcla.24781
work_keys_str_mv AT wanglimei hsacirc0092887targetingmir4905pube2tpromotespaclitaxelresistanceinnonsmallcelllungcancer
AT zhangzhiyong hsacirc0092887targetingmir4905pube2tpromotespaclitaxelresistanceinnonsmallcelllungcancer
AT tianhui hsacirc0092887targetingmir4905pube2tpromotespaclitaxelresistanceinnonsmallcelllungcancer